Sugi Predict

Sugi Predict / Compounds / SCHEMBL1151050

SCHEMBL1151050

SCHEMBL1151050

CC1CC(C)CN(C(=O)Cn2cc(CS(C)(=O)=O)n3c(=O)c(O)c(C(=O)NCc4ccc(F)cc4S(=O)(=O)N(C)C)nc23)C1

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 1/20 0.35
▸ KMT2A Q03164 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CYP2C9 P11712 1/20 0.32
▸ GRIN2B Q13224 1/20 0.32
▸ SLC22A2 O15244 5/20 0.32
▸ KDM4E B2RXH2 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ TMEM97 Q5BJF2 1/20 0.30
▸ ABCG2 Q9UNQ0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1150433 0.92 KCNH2 (0.34) KCNH2KMT2AMEN1ALDH1A1CYP2C9
SCHEMBL1151051 0.85 MEN1 (0.33) KMT2AMEN1ALDH1A1GRIN2BTSHR
SCHEMBL12862259 0.85 CALCA (0.36) KCNH2KMT2AMEN1ALDH1A1CYP2C9
SCHEMBL1151053 0.84 KCNH2 (0.35) KCNH2KMT2ACYP2C9GRIN2BSLC22A2
SCHEMBL1150530 0.80 ALDH1A1 (0.37) KMT2AMEN1ALDH1A1KDM4E
SCHEMBL12862257 0.78 CALCA (0.36) KCNH2CYP2C9
SCHEMBL12862284 0.77 ALDH1A1 (0.38) KMT2AMEN1ALDH1A1CYP2C9KDM4E
SCHEMBL1150434 0.77 MEN1 (0.33) KMT2AMEN1ALDH1A1GRIN2BTSHR
SCHEMBL12862266 0.76 CALCA (0.40) KCNH2CYP2C9GRIN2B
SCHEMBL12862270 0.73 CALCA (0.37) KCNH2ALDH1A1CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2291377-B1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2015-02-18 — — EP disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
EP-2291377-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF Avexa Limited (AU) 2011-03-09 — — EP disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 — — WO disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF TPMT, DPYD, IMPDH1 KCNH2 1681/4885KMT2A 1900/4885MEN1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.